News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Emiliem, Inc. And MIR Preclinical Services Sign Cancer Pharmacology Agreement


1/12/2007 10:24:52 AM

Emiliem, Inc. and MIR Preclinical Services (MIR) announce the signing of an agreement whereby MIR will conduct broad preclinical services for Emiliem on its multi-kinase inhibitors created through its K-STAR technology. The agreement includes preclinical oncology assessments and evaluations of Emiliem’s novel anti-tumor agents using xenograft, orthotopic and transgenic animal models. Dale E. Johnson, Pharm.D., Ph.D., President and CEO of Emiliem, stated “We are extremely pleased to form this relationship with MIR whose expertise and technologies will be instrumental for our quest to create innovative clinical drug development candidates. MIR employs a wide array of novel imaging technologies in its preclinical models to measure response to therapy at anatomical, functional and molecular levels. Many of these imaging technologies can be translated into clinical benchmarks which will eventually speed our evaluation of therapeutic response in cancer patients.”


Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES